Fielder Capital Group LLC Purchases New Position in Zoetis Inc. (NYSE:ZTS)

Fielder Capital Group LLC acquired a new position in shares of Zoetis Inc. (NYSE:ZTS) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,163 shares of the company’s stock, valued at approximately $229,000.

Several other hedge funds have also recently bought and sold shares of the stock. UNIVEST FINANCIAL Corp increased its position in shares of Zoetis by 0.8% during the 4th quarter. UNIVEST FINANCIAL Corp now owns 20,593 shares of the company’s stock worth $4,064,000 after purchasing an additional 163 shares in the last quarter. Maryland State Retirement & Pension System increased its holdings in shares of Zoetis by 1.1% during the fourth quarter. Maryland State Retirement & Pension System now owns 36,034 shares of the company’s stock worth $7,112,000 after buying an additional 384 shares in the last quarter. Private Advisor Group LLC raised its stake in shares of Zoetis by 45.9% in the fourth quarter. Private Advisor Group LLC now owns 26,593 shares of the company’s stock valued at $5,249,000 after acquiring an additional 8,369 shares during the last quarter. Spire Wealth Management boosted its holdings in shares of Zoetis by 1.8% in the 4th quarter. Spire Wealth Management now owns 25,539 shares of the company’s stock worth $4,811,000 after acquiring an additional 455 shares in the last quarter. Finally, Valley Brook Capital Group Inc. increased its holdings in Zoetis by 4.8% during the 4th quarter. Valley Brook Capital Group Inc. now owns 2,168 shares of the company’s stock valued at $428,000 after purchasing an additional 100 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts recently issued reports on ZTS shares. Stifel Nicolaus reduced their price target on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, April 30th. StockNews.com cut shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. Barclays dropped their price objective on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research report on Tuesday, April 23rd. The Goldman Sachs Group decreased their price objective on Zoetis from $223.00 to $196.00 and set a “buy” rating on the stock in a research report on Monday. Finally, Piper Sandler reissued an “overweight” rating and issued a $195.00 target price (down from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $212.38.

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 363 shares of the firm’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $197.74, for a total transaction of $71,779.62. Following the sale, the executive vice president now owns 20,417 shares of the company’s stock, valued at $4,037,257.58. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Over the last ninety days, insiders have sold 2,209 shares of company stock worth $371,293. Corporate insiders own 0.16% of the company’s stock.

Zoetis Trading Down 0.7 %

ZTS traded down $1.12 during midday trading on Monday, reaching $165.95. 3,080,329 shares of the company were exchanged, compared to its average volume of 3,177,335. The stock has a market capitalization of $75.72 billion, a P/E ratio of 31.98, a PEG ratio of 2.62 and a beta of 0.86. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92. The stock’s 50-day simple moving average is $168.25 and its 200 day simple moving average is $178.92. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.94 and a current ratio of 3.33.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, May 2nd. The company reported $1.38 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.04. The business had revenue of $2.19 billion for the quarter, compared to analyst estimates of $2.14 billion. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. Zoetis’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same quarter last year, the firm earned $1.31 EPS. As a group, analysts forecast that Zoetis Inc. will post 5.77 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Friday, April 19th will be paid a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a yield of 1.04%. The ex-dividend date of this dividend is Thursday, April 18th. Zoetis’s payout ratio is presently 33.33%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.